BIopharmaceutical and lifesciences companies Eris Lifesciences and MJ Biopharm, agreed to form a 70:30 joint venture Eris MJ Biopharm, an insulin maker. Financial terms were not disclosed. "With the formation of this JV with MJ, we are taking our commitment a step further. Over the next 10-15 years, growth in diabetes care will be driven by DPP4-SGLT2 combinations, Insulin Analogues and GLP1 agonists, given the superior clinical evidence on their ability to provide better glycemic control, cardio-renal protection, and weight management," Amit Bakshi, Eris Lifesciences Chairman and Managing Director.